{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:14:45Z","timestamp":1782821685291,"version":"3.54.5"},"reference-count":203,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Acute myeloid leukemia (AML), the second most common type of leukemia in children, is a heterogeneous disease known to be caused by genetic, epigenetic, and transcriptional changes, predominantly somatic and germline abnormalities. Despite significant improvement of overall survival rates, the prognosis of pediatric AML remains unfavorable in comparison with acute lymphoblastic leukemia (ALL), especially in relapsed or refractory settings. The current status and future directions are focused on establishing an accurate diagnosis and treatment strategies based on the genomic background. Next-generation sequencing (NGS) technologies enable a broader understanding of the basis of the disease for the purpose of determining pathology-associated mutations and additional prognostic biomarkers in pediatric AML. This review focuses on providing an overview of the known and possible prognostic factors, as well as genetic landscape of pediatric AML patients and how it can be used to accurately differentiate and risk stratify patients. It also presents potential candidate modifications for risk adjustment and targeted therapy. Furthermore, we describe in this article a case of a 22-month-old male patient with relapsed M5 high-risk group (HRG) AML with complex karyotype. Due to belonging to the HRG, as well as unsatisfactory chemotherapy response, the patient underwent matched unrelated donor (MUD) stem cell transplantation (SCT).<\/jats:p>","DOI":"10.3390\/ijms26199269","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T10:27:53Z","timestamp":1758623273000},"page":"9269","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Novel Approach to Prognostic Factors and Risk Stratification in Pediatric AML: Case Report and Literature Review"],"prefix":"10.3390","volume":"26","author":[{"given":"Maria","family":"Le\u015bniak","sequence":"first","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sekunda","sequence":"additional","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-6764","authenticated-orcid":false,"given":"Emilia","family":"Kamizela","sequence":"additional","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Deleszkiewicz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantology, University Children\u2019s Hospital in Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Ozyga\u0142a","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Zawitkowska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"ref_1","unstructured":"(2025, July 19). Acute Myeloid Leukemia\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021011694","article-title":"How I Treat Pediatric Acute Myeloid Leukemia","volume":"138","author":"Rubnitz","year":"2021","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00277-014-2072-6","article-title":"Prognostic Significance of FLT3 Internal Tandem Duplication, Nucleophosmin 1, and CEBPA Gene Mutations for Acute Myeloid Leukemia Patients with Normal Karyotype and Younger than 60 Years: A Systematic Review and Meta-Analysis","volume":"93","author":"Port","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kuhlen, M., Klusmann, J.-H., and Hoell, J.I. (2019). Molecular Approaches to Treating Pediatric Leukemias. Front. Pediatr., 7.","DOI":"10.3389\/fped.2019.00368"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and Challenges in the Treatment of Pediatric Acute Myeloid Leukemia: A Retrospective Analysis of the AML-BFM Trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric Acute Lymphoblastic Leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1542\/pir.2018-0192","article-title":"Leukemia in Children","volume":"40","author":"Kaplan","year":"2019","journal-title":"Pediatr. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_9","unstructured":"(2025, July 19). National Childhood Cancer Registry Explorer (NCCR*Explorer), Available online: https:\/\/nccrexplorer.ccdi.cancer.gov\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/jcm4010127","article-title":"Pediatric AML: From Biology to Clinical Management","volume":"4","author":"Zwaan","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pcl.2014.09.007","article-title":"Pediatric Acute Myeloid Leukemia: Biology and Therapeutic Implications of Genomic Variants","volume":"62","author":"Tarlock","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tomizawa, D., and Tsujimoto, S.-I. (2023). Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15164171"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1177\/1078155218817816","article-title":"FLAG\/FLAG-IDA Regimen for Children with Relapsed\/Refractory Acute Leukemia in the Era of Targeted Novel Therapies","volume":"25","author":"Mustafa","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bjh.12947","article-title":"How I Treat Paediatric Relapsed Acute Myeloid Leukaemia","volume":"166","author":"Kaspers","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular Minimal Residual Disease in Acute Myeloid Leukemia","volume":"378","author":"Grob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bertuccio, S.N., Anselmi, L., Masetti, R., Lonetti, A., Cerasi, S., Polidori, S., Serravalle, S., and Pession, A. (2021). Exploiting Clonal Evolution to Improve the Diagnosis and Treatment Efficacy Prediction in Pediatric AML. Cancers, 13.","DOI":"10.3390\/cancers13091995"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/hematology.2022000358","article-title":"The Evolution of Targeted Therapy in Pediatric AML: Gemtuzumab Ozogamicin, FLT3\/IDH\/BCL2 Inhibitors, and Other Therapies","volume":"2022","author":"Pommert","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ciciarello, M., Corradi, G., Forte, D., Cavo, M., and Curti, A. (2021). Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?. Cancers, 13.","DOI":"10.3390\/cancers13215319"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone Marrow Central Memory and Memory Stem T-Cell Exhaustion in AML Patients Relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2327916","DOI":"10.1080\/16078454.2024.2327916","article-title":"Epidemiological Characteristics and Influencing Factors of Acute Leukemia in Children and Adolescents and Adults: A Large Population-Based Study","volume":"29","author":"Liu","year":"2024","journal-title":"Hematology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.canep.2015.06.009","article-title":"Prognostic Factors of Childhood and Adolescent Acute Myeloid Leukemia (AML) Survival: Evidence from Four Decades of US Population Data","volume":"39","author":"Hossain","year":"2015","journal-title":"Cancer Epidemiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3324\/haematol.2016.146175","article-title":"Effect of Age and Body Weight on Toxicity and Survival in Pediatric Acute Myeloid Leukemia: Results from NOPHO-AML 2004","volume":"101","author":"Abrahamsson","year":"2016","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"83767","DOI":"10.18632\/oncotarget.11765","article-title":"Impact of Age on the Survival of Pediatric Leukemia: An Analysis of 15083 Children in the SEER Database","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1097\/HS9.0000000000000316","article-title":"Is Acute Myeloblastic Leukemia in Children Under 2 Years of Age a Specific Entity? A Report from the FRENCH ELAM02 Study Group","volume":"3","author":"Blais","year":"2019","journal-title":"Hemasphere"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.16203","article-title":"Patients Aged Less than 3 Years with Acute Myeloid Leukaemia Characterize a Molecularly and Clinically Distinct Subgroup","volume":"188","author":"Hara","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pawi\u0144ska-W\u0105sikowska, K., Czoga\u0142a, M., Bukowska-Strakova, K., Surman, M., Rygielska, M., Ksi\u0105\u017cek, T., Sadowska, B., Pac, A., Skalska-Sadowska, J., and Samborska, M. (2024). Treatment Outcomes of Adolescents Compared to Younger Pediatric Patients with Acute Myeloid Leukemia: Do They Need a Special Approach?. Cancers, 16.","DOI":"10.3390\/cancers16061145"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2017-12-778472","article-title":"Treatment Strategies for Adolescent and Young Adult Patients with Acute Myeloid Leukemia","volume":"132","author":"Freyer","year":"2018","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1002\/cam4.3023","article-title":"Prognostic Stratification of Molecularly and Clinically Distinct Subgroup in Children with Acute Monocytic Leukemia","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/bloodadvances.2021004735","article-title":"Association of Race and Ethnicity with Clinical Phenotype, Genetics, and Survival in Pediatric Acute Myeloid Leukemia","volume":"5","author":"Conneely","year":"2021","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/2159-8290.CD-20-1579","article-title":"Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia","volume":"11","author":"Bhatnagar","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1182\/bloodadvances.2022007544","article-title":"High Early Death Rates, Treatment Resistance, and Short Survival of Black Adolescents and Young Adults with AML","volume":"6","author":"Larkin","year":"2022","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e27583","DOI":"10.1002\/pbc.27583","article-title":"Comparable On-Therapy Mortality and Supportive Care Requirements in Black and White Patients Following Initial Induction for Pediatric Acute Myeloid Leukemia","volume":"66","author":"Li","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1080\/10428194.2019.1574002","article-title":"Disparities in Pediatric Acute Myeloid Leukemia (AML) Clinical Trial Enrollment","volume":"60","author":"Winestone","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e2411726","DOI":"10.1001\/jamanetworkopen.2024.11726","article-title":"Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia","volume":"7","author":"Lamba","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/cam4.5188","article-title":"Association Between Body Mass Index at Diagnosis and Outcomes in Chinese Children with Newly Diagnosed Acute Lymphoblastic Leukemia","volume":"12","author":"Hu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cncr.34529","article-title":"Body Mass Index during Maintenance Therapy and Relapse Risk in Children with Acute Lymphoblastic Leukemia: A Children\u2019s Oncology Group Report","volume":"129","author":"Wadhwa","year":"2023","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1002\/cncr.27640","article-title":"Effect of Body Mass Index on the Outcome of Children with Acute Myeloid Leukemia","volume":"118","author":"Inaba","year":"2012","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/bloodadvances.2021006090","article-title":"Changes in Body Mass Index, Weight, and Height in Children with Acute Myeloid Leukemia and the Associations with Outcome","volume":"6","author":"Iijima","year":"2022","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wen, X., He, H., Zhang, R., Wu, Y., Zhang, Y., Lin, W., Yu, J., Fan, J., Huang, P., and Chen, J. (2024). Longitudinal Changes in Body Mass Index, Height, and Weight in Children with Acute Myeloid Leukemia. BMC Pediatr., 24.","DOI":"10.1186\/s12887-024-04740-z"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Dong, L., Dai, G., and Zhao, J. (2024). Impact of Body Mass Index at Diagnosis on Outcomes of Pediatric Acute Leukemia: A Systematic Review and Meta-Analysis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0302879"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.phoj.2021.01.001","article-title":"Profile of down Syndrome\u2013Associated Malignancies: Epidemiology, Clinical Features and Therapeutic Aspects","volume":"6","author":"Shimada","year":"2021","journal-title":"Pediatr. Hematol. Oncol. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/17474086.2022.2044780","article-title":"Hematological Disorders in Children with Down Syndrome","volume":"15","author":"Triarico","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kosmidou, A., Tragiannidis, A., and Gavriilaki, E. (2023). Myeloid Leukemia of Down Syndrome. Cancers, 15.","DOI":"10.3390\/cancers15133265"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3324\/haematol.2015.133520","article-title":"Twenty Years of the Italian Fanconi Anemia Registry: Where We Stand and What Remains to Be Learned","volume":"101","author":"Risitano","year":"2016","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12288-014-0424-y","article-title":"Fanconi Anemia with MDS RAEB-2 Rapidly Progressing to AML in a 5-Year-Old Boy","volume":"30","author":"Rama","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0165-4608(01)00392-2","article-title":"Chromosomal Aberrations in Bloom Syndrome Patients with Myeloid Malignancies","volume":"128","author":"Poppe","year":"2001","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1365-2141.2002.03585.x","article-title":"Shwachman-Diamond Syndrome","volume":"118","author":"Dror","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ejhg.2011.37","article-title":"Cancer Risk in Patients with Noonan Syndrome Carrying a PTPN11 Mutation","volume":"19","author":"Jongmans","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"101197","DOI":"10.1016\/j.beha.2020.101197","article-title":"Germline Predisposition in Myeloid Neoplasms: Unique Genetic and Clinical Features of GATA2 Deficiency and SAMD9\/SAMD9L Syndromes","volume":"33","author":"Sahoo","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa041331","article-title":"Mutation of CEBPA in Familial Acute Myeloid Leukemia","volume":"351","author":"Smith","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3324\/haematol.2015.130799","article-title":"Whole Exome Sequencing Reveals a C-Terminal Germline Variant in CEBPA-Associated Acute Myeloid Leukemia: 45-Year Follow up of a Large Family","volume":"101","author":"Pathak","year":"2016","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/10428194.2020.1861276","article-title":"A Case of Acute Myeloid Leukemia with Unusual Germline CEBPA Mutation: Lessons Learned about Mutation Detection, Location, and Penetrance","volume":"62","author":"Mendoza","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.seminhematol.2017.04.001","article-title":"Familial CEBPA-Mutated Acute Myeloid Leukemia","volume":"54","author":"Tawana","year":"2017","journal-title":"Semin. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10689-023-00329-0","article-title":"Hereditary Acute Myeloid Leukemia Associated with C-Terminal CEBPA Germline Variants","volume":"22","author":"Harrigan","year":"2023","journal-title":"Fam. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.2019000937","article-title":"Secondary Leukemia in Patients with Germline Transcription Factor Mutations (RUNX1, GATA2, CEBPA)","volume":"136","author":"Brown","year":"2020","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/ng.913","article-title":"Heritable GATA2 Mutations Associated with Familial Myelodysplastic Syndrome and Acute Myeloid Leukemia","volume":"43","author":"Hahn","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/humu.24271","article-title":"GATA2 Deficiency Syndrome: A Decade of Discovery","volume":"42","author":"Homan","year":"2021","journal-title":"Hum. Mutat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1038\/s41375-018-0134-9","article-title":"GATA2 Monoallelic Expression Underlies Reduced Penetrance in Inherited GATA2-Mutated MDS\/AML","volume":"32","author":"Tawana","year":"2018","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.3177","article-title":"Germline ETV6 Mutations in Familial Thrombocytopenia and Hematologic Malignancy","volume":"47","author":"Zhang","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12185-017-2259-4","article-title":"Germline ETV6 Mutations and Predisposition to Hematological Malignancies","volume":"106","author":"Feurstein","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical Effect of Point Mutations in Myelodysplastic Syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The Genetic Basis of Early T-Cell Precursor Acute Lymphoblastic Leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1084\/jem.20112239","article-title":"ETV6 Mutations in Early Immature Human T Cell Leukemias","volume":"208","author":"Haydu","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ng.3253","article-title":"Germline Mutations in ETV6 Are Associated with Thrombocytopenia, Red Cell Macrocytosis and Predisposition to Lymphoblastic Leukemia","volume":"47","author":"Noetzli","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S1470-2045(15)00369-1","article-title":"Germline Genetic Variation in ETV6 and Risk of Childhood Acute Lymphoblastic Leukaemia: A Systematic Genetic Study","volume":"16","author":"Moriyama","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/leu.2009.210","article-title":"Novel RUNX1 Mutations in Familial Platelet Disorder with Enhanced Risk for Acute Myeloid Leukemia: Clues for Improved Identification of the FPD\/AML Syndrome","volume":"24","author":"Jongmans","year":"2010","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1182\/blood-2008-07-168260","article-title":"High Frequency of RUNX1 Biallelic Alteration in Acute Myeloid Leukemia Secondary to Familial Platelet Disorder","volume":"113","author":"Preudhomme","year":"2009","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/bloodadvances.2019000901","article-title":"RUNX1-Mutated Families Show Phenotype Heterogeneity and a Somatic Mutation Profile Unique to Germline Predisposed AML","volume":"4","author":"Brown","year":"2020","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/bloodadvances.2019000644","article-title":"ClinGen Myeloid Malignancy Variant Curation Expert Panel Recommendations for Germline RUNX1 Variants","volume":"3","author":"Luo","year":"2019","journal-title":"Blood Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.3324\/haematol.2021.278762","article-title":"The RUNX1 Database (RUNX1db): Establishment of an Expert Curated RUNX1 Registry and Genomics Database as a Public Resource for Familial Platelet Disorder with Myeloid Malignancy","volume":"106","author":"Homan","year":"2021","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"F\u00f6rster, A., Decker, M., Schlegelberger, B., and Ripperger, T. (2022). Beyond Pathogenic RUNX1 Germline Variants: The Spectrum of Somatic Alterations in RUNX1-Familial Platelet Disorder with Predisposition to Hematologic Malignancies. Cancers, 14.","DOI":"10.3390\/cancers14143431"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.beha.2019.05.001","article-title":"Hereditary Myeloid Malignancies","volume":"32","author":"Rafei","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1182\/blood-2011-02-336537","article-title":"Mutations in ANKRD26 Are Responsible for a Frequent Form of Inherited Thrombocytopenia: Analysis of 78 Patients from 21 Families","volume":"117","author":"Noris","year":"2011","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ajhg.2010.12.006","article-title":"Mutations in the 5\u2032 UTR of ANKRD26, the Ankirin Repeat Domain 26 Gene, Cause an Autosomal-Dominant Form of Inherited Thrombocytopenia, THC2","volume":"88","author":"Pippucci","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00431-015-2549-x","article-title":"Childhood Diagnosis of Genetic Thrombocytopenia with Mutation in the Ankyrine Repeat Domain 26 Gene","volume":"174","author":"Boutroux","year":"2015","journal-title":"Eur. J. Pediatr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni Syndrome from TP53 Mutation Carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/0008-5472.CAN-19-0728","article-title":"Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts","volume":"80","author":"Shin","year":"2020","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li-Fraumeni and Heritable TP53-Related Cancer Syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41375-021-01163-y","article-title":"Clinical and Genetic Characteristics of Children with Acute Lymphoblastic Leukemia and Li-Fraumeni Syndrome","volume":"35","author":"Winter","year":"2021","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"a003210","DOI":"10.1101\/mcs.a003210","article-title":"Hematologic Malignancies and Li-Fraumeni Syndrome","volume":"5","author":"Swaminathan","year":"2019","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bjh.17006","article-title":"Prevalence of Germline GATA2 and SAMD9\/9L Variants in Paediatric Haematological Disorders with Monosomy 7","volume":"191","author":"Yoshida","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ng.3569","article-title":"SAMD9 Mutations Cause a Novel Multisystem Disorder, MIRAGE Syndrome, and Are Associated with Loss of Chromosome 7","volume":"48","author":"Narumi","year":"2016","journal-title":"Nat Genet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41375-018-0074-4","article-title":"SAMD9 and SAMD9L in Inherited Predisposition to Ataxia, Pancytopenia, and Myeloid Malignancies","volume":"32","author":"Davidsson","year":"2018","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e121086","DOI":"10.1172\/jci.insight.121086","article-title":"Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes","volume":"3","author":"Wong","year":"2018","journal-title":"JCI Insight."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ijlh.12212","article-title":"Leukocytosis","volume":"36","author":"George","year":"2014","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Kittivisuit, S., Jongthitinon, N., Sripornsawan, P., Songthawee, N., Chavananon, S., Limratchapong, C., McNeil, E.B., and Chotsampancharoen, T. (2023). Hyperleukocytosis in Childhood Acute Leukemia: Early Complications and Survival Outcomes. Cancers, 15.","DOI":"10.3390\/cancers15123072"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12185-023-03665-0","article-title":"Pediatric Acute Myeloid Leukemia and Hyperleukocytosis with WBC Count Greater than 50 \u00d7 109\/L","volume":"118","author":"Zhang","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/S2352-3026(17)30052-2","article-title":"Worldwide Comparison of Survival from Childhood Leukaemia for 1995-2009, by Subtype, Age, and Sex (CONCORD-2): A Population-Based Study of Individual Data for 89\u2008828 Children from 198 Registries in 53 Countries","volume":"4","author":"Bonaventure","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Bewersdorf, J.P., and Zeidan, A.M. (2020). Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. Cells, 9.","DOI":"10.3390\/cells9102310"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/16078454.2020.1859169","article-title":"Hyperleukocytosis Predicts Inferior Clinical Outcome in Pediatric Acute Myeloid Leukemia","volume":"25","author":"Xu","year":"2020","journal-title":"Hematology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1634\/theoncologist.12-3-341","article-title":"Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia","volume":"12","author":"Meshinchi","year":"2007","journal-title":"Oncologist"},{"key":"ref_95","first-page":"214","article-title":"Relapsed Childhood Acute Myeloid Leukemia: Prognostic Factors and Outcomes: Experience from a Single Oncology Center","volume":"54","author":"Stankiewicz","year":"2023","journal-title":"Acta Haematol. Pol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1586\/era.12.101","article-title":"All-Trans Retinoic Acid in the Treatment of Pediatric Acute Promyelocytic Leukemia","volume":"12","author":"Masetti","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10555-020-09846-1","article-title":"The Genomics of Acute Myeloid Leukemia in Children","volume":"39","author":"Conneely","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-017-0396-0","article-title":"Hh\/Gli Antagonist in Acute Myeloid Leukemia with CBFA2T3-GLIS2 Fusion Gene","volume":"10","author":"Masetti","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The Molecular Landscape of Pediatric Acute Myeloid Leukemia Reveals Recurrent Structural Alterations and Age-Specific Mutational Interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.30220","article-title":"Changes in Cytogenetics and Molecular Genetics in Acute Myeloid Leukemia from Childhood to Adult Age Groups","volume":"122","author":"Creutzig","year":"2016","journal-title":"Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.2217\/fon-2020-0505","article-title":"Uncommon Cytogenetic Abnormalities Identifying High-Risk Acute Myeloid Leukemia in Children","volume":"16","author":"Masetti","year":"2020","journal-title":"Future Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nm.4125","article-title":"Distinct Evolution and Dynamics of Epigenetic and Genetic Heterogeneity in Acute Myeloid Leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.22806","article-title":"Clonal Evolution of Acute Myeloid Leukemia from Diagnosis to Relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-15-1015","article-title":"Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse","volume":"76","author":"Farrar","year":"2016","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/bjh.14247","article-title":"Whole-Exome Sequencing Reveals the Spectrum of Gene Mutations and the Clonal Evolution Patterns in Paediatric Acute Myeloid Leukaemia","volume":"175","author":"Shiba","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"56746","DOI":"10.18632\/oncotarget.10778","article-title":"Genomic Complexity and Dynamics of Clonal Evolution in Childhood Acute Myeloid Leukemia Studied with Whole-Exome Sequencing","volume":"7","author":"Masetti","year":"2016","journal-title":"Oncotarget"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.18632\/oncotarget.23448","article-title":"SALL1 Expression in Acute Myeloid Leukemia","volume":"9","author":"Salman","year":"2018","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/Measurable Residual Disease in AML: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/14737140.2021.1860763","article-title":"Measurable Residual Disease in Pediatric Acute Myeloid Leukemia: A Systematic Review","volume":"21","author":"Segerink","year":"2021","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14737140.2018.1428091","article-title":"Clinical Challenges in de Novo Pediatric Acute Myeloid Leukemia","volume":"18","author":"Klein","year":"2018","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of Measurable Residual Disease with Survival Outcomes in Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood-2018-01-828145","article-title":"Consensus on MRD in AML?","volume":"131","author":"Paietta","year":"2018","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41409-024-02481-2","article-title":"Measurable Residual Disease Testing and Allogeneic Hematopoietic Cell Transplantation for AML: Adapting Pre-MEASURE to Clinical Practice","volume":"60","author":"Shaffer","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical Aspects of Flow Cytometry-Based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"Hemasphere"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.leu.2403405","article-title":"MRD Parameters Using Immunophenotypic Detection Methods Are Highly Reliable in Predicting Survival in Acute Myeloid Leukaemia","volume":"18","author":"Feller","year":"2004","journal-title":"Leukemia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2018.11.014","article-title":"Immunophenotypic Measurable Residual Disease (MRD) in Acute Myeloid Leukemia: Is Multicentric MRD Assessment Feasible?","volume":"76","author":"Brooimans","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1002\/cpcy.73","article-title":"Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr. Protoc. Cytom."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable Residual Disease Testing in Acute Myeloid Leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ngai, L.L., Kelder, A., Janssen, J.J.W.M., Ossenkoppele, G.J., and Cloos, J. (2020). MRD Tailored Therapy in AML: What We Have Learned So Far. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.603636"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2019-01-894279","article-title":"Genetic Susceptibility to Breast Cancer in Lymphoma Survivors","volume":"133","author":"Allan","year":"2019","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1182\/blood.V99.10.3517","article-title":"A White Blood Cell Index as the Main Prognostic Factor in t(8;21) Acute Myeloid Leukemia (AML): A Survey of 161 Cases from the French AML Intergroup","volume":"99","author":"Nguyen","year":"2002","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Wilde, L., Cooper, J., Wang, Z.-X., and Liu, J. (2019). Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML). Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01016"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/bloodadvances.2019000168","article-title":"An Update on the Molecular Pathogenesis and Potential Therapeutic Targeting of AML with t(8;21)(Q22;Q22.1);RUNX1-RUNX1T1","volume":"4","author":"Aljurf","year":"2020","journal-title":"Blood Adv."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"46","DOI":"10.24287\/1726-1708-2021-20-1-46-53","article-title":"Immunophenotypic characterization of pediatric acute myeloid leukemia with inv(16)(p13.1q22)\/t(16;16)(p13.1;q22)\/CBFb-MYH11","volume":"20","author":"Mikhailova","year":"2021","journal-title":"Pediatr. Hematol. Oncol. Immunopathol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.celrep.2019.12.026","article-title":"CBF\u03b2-SMMHC Affects Genome-Wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia","volume":"30","author":"Cordonnier","year":"2020","journal-title":"Cell Rep."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Papadakis, S., Liapis, I., Papadhimitriou, S.I., Spanoudakis, E., Kotsianidis, I., and Liapis, K. (2024). Approach to Acute Myeloid Leukemia with Increased Eosinophils and Basophils. J. Clin. Med., 13.","DOI":"10.20944\/preprints202401.0994.v1"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MOH.0000000000000124","article-title":"Emerging Diagnostic and Therapeutic Approaches in Core Binding Factor Acute Myeloid Leukaemia","volume":"22","author":"Ustun","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2015.61.1947","article-title":"Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results from an International Retrospective Study by the International Berlin-Frankfurt-M\u00fcnster Study Group","volume":"33","author":"Klein","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ajh.23821","article-title":"Core-Binding Factor Acute Myeloid Leukemia: Heterogeneity, Monitoring, and Therapy","volume":"89","author":"Solh","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hon.2951","article-title":"CEBPA Are Independent Good Prognostic Factors in Pediatric Acute Myeloid Leukemia","volume":"40","author":"Liao","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.2020009652","article-title":"CEBPA-bZip Mutations Are Associated with Favorable Prognosis in de Novo AML: A Report from the Children\u2019s Oncology Group","volume":"138","author":"Tarlock","year":"2021","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MOP.0000000000000855","article-title":"Pediatric Acute Myeloid Leukemia: Updates on Biology, Risk Stratification, and Therapy","volume":"32","author":"Elgarten","year":"2020","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current Status and Future Perspectives in Targeted Therapy of NPM1-Mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41375-024-02476-4","article-title":"Functions of the Native NPM1 Protein and Its Leukemic Mutant","volume":"39","author":"Falini","year":"2025","journal-title":"Leukemia"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 Mutations in Acute Myeloid Leukemia: Therapeutic Paradigm beyond Inhibitor Development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1002\/ctm2.933","article-title":"Direct Targeted Therapy for MLL-Fusion-Driven High-Risk Acute Leukaemias","volume":"12","author":"Cantilena","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"szae089","DOI":"10.1093\/stcltm\/szae089","article-title":"Targeting Chromatin Modifying Complexes in Acute Myeloid Leukemia","volume":"14","author":"Schurer","year":"2025","journal-title":"Stem Cells Transl. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A Recombinome of Acute Leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.exphem.2023.06.001","article-title":"The YEATS Domain Epigenetic Reader Proteins ENL and AF9 and Their Therapeutic Value in Leukemia","volume":"124","author":"Hu","year":"2023","journal-title":"Exp. Hematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40164-023-00445-8","article-title":"Modelling Acquired Resistance to DOT1L Inhibition Exhibits the Adaptive Potential of KMT2A-Rearranged Acute Lymphoblastic Leukemia","volume":"12","author":"Schneider","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-022-01251-1","article-title":"Targeting the Histone H3 Lysine 79 Methyltransferase DOT1L in MLL-Rearranged Leukemias","volume":"15","author":"Yi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Quessada, J., Cuccuini, W., Saultier, P., Loosveld, M., Harrison, C.J., and Lafage-Pochitaloff, M. (2021). Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge. Genes, 12.","DOI":"10.3390\/genes12060924"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-139189","article-title":"Improved Outcome in Pediatric AML\u2014The AML-BFM 2012 Study","volume":"136","author":"Waack","year":"2020","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2018-05-849059","article-title":"Prognostic Impact of t(16;21)(P11;Q22) and t(16;21)(Q24;Q22) in Pediatric AML: A Retrospective Study by the I-BFM Study Group","volume":"132","author":"Noort","year":"2018","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel Prognostic Subgroups in Childhood 11q23\/MLL-Rearranged Acute Myeloid Leukemia: Results of an International Retrospective Study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2020.04.038","article-title":"Paediatric Strategy Forum for Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents: ACCELERATE in Collaboration with the European Medicines Agency with Participation of the Food and Drug Administration","volume":"136","author":"Pearson","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.5045\/br.2020.S002","article-title":"Treatments for Children and Adolescents with AML","volume":"55","author":"Kim","year":"2020","journal-title":"Blood Res."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Obsza\u0144ski, P., Koz\u0142owska, A., Wa\u0144cowiat, J., Twardowska, J., Lejman, M., and Zawitkowska, J. (2022). Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia. Molecules, 27.","DOI":"10.3390\/molecules27123911"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/08880018.2025.2453861","article-title":"Pediatric AML: State of the Art and Future Directions","volume":"42","author":"Iyer","year":"2025","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Leger, K.J., Absalon, M.J., Demissei, B.G., Smith, A.M., Gerbing, R.B., Alonzo, T.A., Narayan, H.K., Hirsch, B.A., Pollard, J.A., and Razzouk, B.I. (2024). Cardiotoxicity of CPX-351 in Children and Adolescents with Relapsed AML: A Children\u2019s Oncology Group Report. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1347547"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1200\/JCO.19.03306","article-title":"Phase I\/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children with Relapsed Acute Myeloid Leukemia: A Report from the Children\u2019s Oncology Group","volume":"38","author":"Cooper","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results from the Phase III Children\u2019s Oncology Group Trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/MPH.0000000000002760","article-title":"Gemtuzumab Ozogamicin Monotherapy Is a Well-Tolerated Palliative Chemotherapy Option in Pediatric Multiply Relapsed Acute Myeloid Leukemia: A Multicenter Case Series and Review of the Literature","volume":"45","author":"Blain","year":"2023","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Stokke, J.L., and Bhojwani, D. (2021). Antibody-Drug Conjugates for the Treatment of Acute Pediatric Leukemia. J. Clin. Med., 10.","DOI":"10.3390\/jcm10163556"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e28979","DOI":"10.1002\/pbc.28979","article-title":"Treatment of Acute Myeloid Leukemia in Children: A Practical Perspective","volume":"68","author":"Egan","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3\/ITD+ Acute Myeloid Leukemia: A Report from the Children\u2019s Oncology Group Protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-01009-3","article-title":"Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy","volume":"23","author":"Conneely","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with Standard Chemotherapy for Children with Acute Myeloid Leukemia Does Not Improve Treatment Outcomes: A Report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"16","DOI":"10.14740\/jh1065","article-title":"Clofarabine in Pediatric Acute Relapsed or Refractory Leukemia: Where Do We Stand on the Bridge to Hematopoietic Stem Cell Transplantation?","volume":"12","author":"Ramiz","year":"2023","journal-title":"J. Hematol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Chen, J., and Glasser, C.L. (2020). New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML). Children, 7.","DOI":"10.3390\/children7020012"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Marszo\u0142ek, A., Le\u015bniak, M., Sekunda, A., Siwek, A., Skiba, Z., Lejman, M., and Zawitkowska, J. (2024). Haploidentical HSCT in the Treatment of Pediatric Hematological Disorders. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126380"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41375-022-01619-9","article-title":"Relapsed Acute Myeloid Leukemia in Children and Adolescents: Current Treatment Options and Future Strategies","volume":"36","author":"Caldwell","year":"2022","journal-title":"Leukemia"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Tseng, S., Lee, M.-E., and Lin, P.-C. (2023). A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment. Pharmaceuticals, 16.","DOI":"10.3390\/ph16111614"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Rasche, M., Zimmermann, M., Steidel, E., Alonzo, T., Aplenc, R., Bourquin, J.-P., Boztug, H., Cooper, T., Gamis, A.S., and Gerbing, R.B. (2021). Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers, 13.","DOI":"10.3390\/cancers13102336"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jtct.2022.06.005","article-title":"Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy","volume":"28","author":"Tarlock","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41375-019-0584-8","article-title":"Hematopoietic Stem Cell Transplantation for Children with Acute Myeloid Leukemia-Results of the AML SCT-BFM 2007 Trial","volume":"34","author":"Sauer","year":"2020","journal-title":"Leukemia"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/bloodadvances.2021005224","article-title":"Clofarabine-Fludarabine-Busulfan in HCT for Pediatric Leukemia: An Effective, Low Toxicity, TBI-Free Conditioning Regimen","volume":"6","author":"Versluijs","year":"2022","journal-title":"Blood Adv."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41409-020-01201-w","article-title":"Hematopoietic Cell Transplant in Pediatric Acute Myeloid Leukemia after Similar Upfront Therapy; a Comparison of Conditioning Regimens","volume":"56","author":"Versluys","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"839.e1","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse Following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"127.e1","DOI":"10.1016\/j.jtct.2022.11.022","article-title":"Targeted Therapy with Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children with Chemorefractory Acute Myeloid Leukemia","volume":"29","author":"Klimentova","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Negotei, C., Colita, A., Mitu, I., Lupu, A.R., Lapadat, M.-E., Popovici, C.E., Crainicu, M., Stanca, O., and Berbec, N.M. (2023). A Review of FLT3 Kinase Inhibitors in AML. J. Clin. Med., 12.","DOI":"10.3390\/jcm12206429"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-Cell Malignancies and Overcoming Therapeutic Resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 Inhibitors for Hematologic Malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e35834","DOI":"10.1002\/cncr.35834","article-title":"Top Advances of the Year: Acute Myeloid Leukemia","volume":"131","author":"Thakur","year":"2025","journal-title":"Cancer"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40272-021-00467-x","article-title":"Targeted Therapy in Pediatric AML: An Evolving Landscape","volume":"23","author":"Jones","year":"2021","journal-title":"Paediatr. Drugs"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical Efficacy of the Potent, Selective Menin-KMT2A Inhibitor JNJ-75276617 (Bleximenib) in KMT2A- and NPM1-Altered Leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"ref_181","first-page":"5481","article-title":"A-1210477, a Selective MCL-1 Inhibitor, Overcomes ABT-737 Resistance in AML","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"101406","DOI":"10.1016\/j.jgo.2022.11.005","article-title":"Hypomethylating Agent-Based Therapies in Older Adults with Acute Myeloid Leukemia\u2014A Joint Review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee","volume":"14","author":"Neuendorff","year":"2023","journal-title":"J. Geriatr. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"San Jos\u00e9-En\u00e9riz, E., Gimenez-Camino, N., Agirre, X., and Prosper, F. (2019). HDAC Inhibitors in Acute Myeloid Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11111794"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00277-017-3148-x","article-title":"The Progress and Current Status of Immunotherapy in Acute Myeloid Leukemia","volume":"96","author":"Yang","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41375-024-02217-7","article-title":"Targeting the Innate Immune System in Pediatric and Adult AML","volume":"38","author":"Perzolli","year":"2024","journal-title":"Leukemia"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Verma, A., Chi, Y.-Y., Malvar, J., Lamble, A., Chaudhury, S., Agarwal, A., Li, H.-T., Liang, G., Leong, R., and Brown, P.A. (2024). Nivolumab Plus 5-Azacitidine in Pediatric Relapsed\/Refractory Acute Myeloid Leukemia (AML): Phase I\/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers, 16.","DOI":"10.3390\/cancers16030496"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/08880018.2017.1383542","article-title":"Checkpoint Inhibition in Pediatric Hematologic Malignancies","volume":"34","author":"Davis","year":"2017","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Epperly, R., Gottschalk, S., and Velasquez, M.P. (2020). Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. Children, 7.","DOI":"10.3390\/children7020014"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.3324\/haematol.2023.283757","article-title":"CD74 Is Expressed in a Subset of Pediatric Acute Myeloid Leukemia Patients and Is a Promising Target for Therapy: A Report from the Children\u2019s Oncology Group","volume":"109","author":"Menssen","year":"2024","journal-title":"Haematologica"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jmoldx.2023.04.004","article-title":"Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid Leukemia","volume":"25","author":"Egyed","year":"2023","journal-title":"J. Mol. Diagn."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/bloodadvances.2022008251","article-title":"Hypodiploidy Has Unfavorable Impact on Survival in Pediatric Acute Myeloid Leukemia: An I-BFM Study Group Collaboration","volume":"7","author":"Hammer","year":"2023","journal-title":"Blood Adv."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Ruan, M., Liu, L., Qi, B., Chen, X., Chang, L., Zhang, A., Liu, F., Wang, S., Liu, X., and Chen, X. (2021). Targeted Next-Generation Sequencing of Circulating Tumor DNA, Bone Marrow, and Peripheral Blood Mononuclear Cells in Pediatric AML. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.666470"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1097\/MPH.0000000000002168","article-title":"Clinical Significance of MicroRNA-29a and MicroRNA-100 Gene Expression in Pediatric Acute Myeloid Leukemia","volume":"44","author":"Said","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Cao, J., Xie, M., Sun, K., Zhao, Y., Zheng, J., Wang, Y., Zheng, Y., Liu, S., and Yu, U. (2024). Development of a Prognostic Model Incorporating a Cuproptosis-Related Signature and CNN3 as a Predictor in Childhood Acute Myelocytic Leukemia. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1494777"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41525-024-00424-w","article-title":"MiRNA Expression as Outcome Predictor in Pediatric AML: Systematic Evaluation of a New Model","volume":"9","author":"Ellson","year":"2024","journal-title":"NPJ Genom. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e9139","DOI":"10.1002\/ccr3.9139","article-title":"A Case of AML with Complex Karyotype and Chromosomal Rearrangement of KMT2A","volume":"12","author":"Minor","year":"2024","journal-title":"Clin. Case Rep."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4103\/ijc.IJC_473_18","article-title":"A Complex Karyotype with t(11;12)(Q23;P13) Translocation with Coexistent Clones of Deletion 5q and Cryptic Deletion 7q in Acute Myeloid Leukemia","volume":"57","author":"Pais","year":"2020","journal-title":"Indian J. Cancer"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000499640","article-title":"A New Complex Karyotype Involving a KMT2A-r Variant Three-Way Translocation in a Rare Clinical Presentation of a Pediatric Patient with Acute Myeloid Leukemia","volume":"157","author":"Othman","year":"2019","journal-title":"Cytogenet. Genome Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The Predictive Value of Hierarchical Cytogenetic Classification in Older Adults with Acute Myeloid Leukemia (AML): Analysis of 1065 Patients Entered into the United Kingdom Medical Research Council AML11 Trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic Analysis Predicts Outcome of Preremission and Postremission Therapy in Adult Acute Myeloid Leukemia: A Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and Age Are Major Determinants of Outcome in Intensively Treated Acute Myeloid Leukemia Patients Older than 60 Years: Results from AMLSG Trial AML HD98-B","volume":"108","author":"Schlenk","year":"2006","journal-title":"Blood"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13039-021-00547-0","article-title":"Cytogenetic and Mutational Analysis and Outcome Assessment of a Cohort of 284 Children with de Novo Acute Myeloid Leukemia Reveal Complex Karyotype as an Adverse Risk Factor for Inferior Survival","volume":"14","author":"Chen","year":"2021","journal-title":"Mol. Cytogenet."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.leukres.2016.09.015","article-title":"Monosomal Karyotype Is Not a Predictor of Dismal Outcome in Childhood de Novo Acute Myeloid Leukemia","volume":"50","author":"Lee","year":"2016","journal-title":"Leuk. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9269\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:36Z","timestamp":1760035656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":203,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199269"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199269","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]}}}